Wednesday 1 May

19.00-21.00 Welcome reception

Thursday 2 May

 Session 1 Overlapping clinical phenotypes - common molecular pathways?

9-9.25 Andreas Brunklaus (Glasgow, UK) The Spectrum of gain of function SCN1A disorders
9.25-9.50 Elena Gardella (Dianalund, DK) Sodium channelopathies: clinical commonalities and differences
9.50-10.15 Sebastian Ortiz (Dianalund, DK) Distrinct clinical phenotypes associated with LOF
vs GOF GABAA-receptor variants

10.15-10.45 Coffee break

Session 1 Continued
10.45-11.10 Carla Marini (Ancona, IT) PRRT2 variants in self-limiting epilepsy, paroxysmal dyskinesia,
and hemiplegic migraine
11.10-11.35 Steffen Syrbe (Heidelberg, GER) The spectrum of CACNA1A-related disorders
11-35-12.00 Robert Lauerer-Braun (Tübingen, GER) CACNA1E variants in Developmental and
Epileptic Encephalopathy with contractures, macrocephaly and dyskinesias
12.00-12.25 Johannes Lemke (Leipzig, GER) GRIN-related disorders: diversification of inheritance pattern,
phenotypic spectrum, and treatment approaches

12.25-13.30 Lunch

13.30-14.15 Kevin Bender (San Francisco, USA) & Stephan Sanders (Oxford, UK) Similar clinical phenotypes -
shared genetic mechanisms?
14-15-14.35 Panel discussion

14.35-15.00 Coffee break

Session 2: Clinical relevance of EEG biomarkers in monogenic epilepsies

15.00-15.25 Roberta Cilio (Brussels, BE) EEG biomarkers in neonatal onset epilepsies
15.25-15.50 Guido Rubboli (Dianalund, DK) EEG phenotyping: Still a valuable tool for genotype-phenotype correlations?
15.50-16.15 Alberto Cossu (Verona, IT) Quantitative EEG biomarkers for STXBP1-related disorders
1615-16.40 Stéphane Auvin (Paris, FR) The usefulness of EEG biomarkers in clinical trials
16.40-17.00 Panel discussion

17.00-18.00 Coffee break

Session 3: Late Breaking News

18.00-19.00 Late breaking news

19.45 Dinner

Friday 3 May

Session 4 Precision Medicine in Genetic Epilepsies: Concepts and Research Strategies

8.30-8.55 Rikke Møller, (Dianalund, DK), Precision medicine in genetic epilepsies 
8.55-9.20 Maurizio Taglialatela (Naples, IT) How can drug repurposing inform us
of dysfunctional mechanisms? Yelds and challenges
9.20-9.45 Snezana Majevic (Melbourne, AUS) Leveragine iPSC-derived disease models
to propel precision medicine treatments for developmental Epilepsies Encephalopathy

9.45-10.10 Massimo Montegazza (Nice, FR) The role of mouse models of genetic epilepsies in precision medicine
 
10.10-10.35 Panel discussion

10.35-11.00 Coffee break

11.00-13.00 Case presentations of precision medicine in genetic epilepsies
13.00-13.30 Matthew C. Walker (London, UK) Therapies of the future
13.30-13.45 Concluding remarks

13.45 Farewell Lunch